Search results for: Antibiotics
Filter search results
OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris
18 December 2019
…The advanced modelling approaches that are used for vaccines could be transferred to antibiotics to model the patterns of transmission and herd immunity. Contracting for new antibiotics needs to move…
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017
31 October 2017
…and the greater value of narrow spectrum antibiotics as compared to broad spectrum antibiotics. A shared view is also that improvements in HTA approaches are considered more likely with collaboration…
A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
19 May 2023
…antibiotics that could inform longer-term financing and reimbursement arrangements and guide prescribing behaviours. Key takeaways Antimicrobial resistance (AMR) threatens our ability to treat common infections, and antibiotic stewardship is critical…
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…Bonnifield and Towse, (2022). Estimating the EU’s Return on Investment from an Ambitious Program to Incentivize New Antibiotics. CGD Brief, December 2022. Available at: https://www.cgdev.org/sites/default/files/estimating-eus-return-investment-ambitious-program-incentivize-new-antibiotics.pdf Van de Wiele et al. (2023)….
OHE Models Incentives for Antibiotic Drug Development
18 March 2014
The OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing the new drugs. A…
R&D for new drugs to tackle AMR is a high-return investment for all EU member states
19 July 2024
…an Ambitious Program to Incentivize New Antibiotics. Policy Brief. Center for Global Development. Available at https://www.cgdev.org/publication/estimating-eus-return-investment-ambitious-program-incentivize-new-antibiotics Towse, A. and Silverman Bonnifield, R. 2022. “An Ambitious USG Advanced Commitment for Subscription-Based Purchasing…
Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
8 November 2023
…needed antibiotics. Share this: Download publication New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this…
Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
2 November 2023
…proposed pull incentive for antibiotic development in the UK by seeking the perspectives of (potential) investors in the antibiotics space. Investors are key stakeholders in the development of new antibiotics,…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
…from investment in antibiotics. Value assessment methods recognising the value of new antibiotics to the whole health system are needed to help match the size of the required monetary incentives…